232 related articles for article (PubMed ID: 28965854)
1. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
Hoang B; Ernsting MJ; Murakami M; Undzys E; Li SD
Int J Pharm; 2014 Aug; 471(1-2):224-33. PubMed ID: 24853460
[TBL] [Abstract][Full Text] [Related]
3. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
4. Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance.
Roy A; Murakami M; Ernsting MJ; Hoang B; Undzys E; Li SD
Mol Pharm; 2014 Aug; 11(8):2592-9. PubMed ID: 24564177
[TBL] [Abstract][Full Text] [Related]
5. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
6. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.
Ernsting MJ; Murakami M; Undzys E; Aman A; Press B; Li SD
J Control Release; 2012 Sep; 162(3):575-81. PubMed ID: 22967490
[TBL] [Abstract][Full Text] [Related]
7. Using Flash Nanoprecipitation To Produce Highly Potent and Stable Cellax Nanoparticles from Amphiphilic Polymers Derived from Carboxymethyl Cellulose, Polyethylene Glycol, and Cabazitaxel.
Bteich J; McManus SA; Ernsting MJ; Mohammed MZ; Prud'homme RK; Sokoll KK
Mol Pharm; 2017 Nov; 14(11):3998-4007. PubMed ID: 28945432
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
[TBL] [Abstract][Full Text] [Related]
9. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
10. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.
Ernsting MJ; Hoang B; Lohse I; Undzys E; Cao P; Do T; Gill B; Pintilie M; Hedley D; Li SD
J Control Release; 2015 May; 206():122-30. PubMed ID: 25804872
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models.
Ernsting MJ; Tang WL; MacCallum NW; Li SD
Biomaterials; 2012 Feb; 33(5):1445-54. PubMed ID: 22079003
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System.
Qu Z; Ren Y; Shen H; Wang H; Shi L; Tong D
Drug Des Devel Ther; 2021; 15():3605-3616. PubMed ID: 34447241
[TBL] [Abstract][Full Text] [Related]
13. Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells.
Ernsting MJ; Tang WL; MacCallum N; Li SD
Bioconjug Chem; 2011 Dec; 22(12):2474-86. PubMed ID: 22014112
[TBL] [Abstract][Full Text] [Related]
14. Current Update of a Carboxymethylcellulose-PEG Conjugate Platform for Delivery of Insoluble Cytotoxic Agents to Tumors.
Yang Y; Bteich J; Li SD
AAPS J; 2017 Mar; 19(2):386-396. PubMed ID: 27873118
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening.
Hongo H; Kosaka T; Suzuki Y; Oya M
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):59-66. PubMed ID: 34593983
[TBL] [Abstract][Full Text] [Related]
16. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
Hongo H; Kosaka T; Oya M
Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
[TBL] [Abstract][Full Text] [Related]
18. Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer.
Qu N; Lee RJ; Sun Y; Cai G; Wang J; Wang M; Lu J; Meng Q; Teng L; Wang D; Teng L
Int J Nanomedicine; 2016; 11():3451-9. PubMed ID: 27555767
[TBL] [Abstract][Full Text] [Related]
19. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
20. Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Kellokumpu-Lehtinen PL; Marttila T; Jekunen A; Hervonen P; Klintrup K; Kataja V; Utriainen T; Luukkaa M; Leskinen M; Pulkkanen K; Kautio AL; Huttunen T
Anticancer Res; 2020 Dec; 40(12):6915-6921. PubMed ID: 33288585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
